表紙:ペニシリン製剤の世界市場(2021年~2028年)
市場調査レポート
商品コード
1024567

ペニシリン製剤の世界市場(2021年~2028年)

Global Penicillin Drug Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
ペニシリン製剤の世界市場(2021年~2028年)
出版日: 2021年08月20日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ペニシリン系医薬品のうち、ペニシリンVは抗生物質で、耳の感染症など、細菌によって引き起こされるさまざまな感染症の治療に使用されます。細菌感染症の増加と、効果的で新しい抗生物質の需要が、予測期間におけるペニシリン製剤市場を牽引する見通しです。

当レポートでは、世界のペニシリン製剤市場を調査し、市場の概要、セグメント・地域別の市場規模および成長率の推移と予測、新型コロナウイルス感染症(COVID-19)の影響分析、市場成長の促進要因および抑制要因の分析、市場機会、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 ペニシリン製剤市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 市場内訳:ソース別
  • 市場内訳:クラス別
  • 市場内訳:投与経路別
  • 市場内訳:地域別

第4章 市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 ペニシリン製剤市場:業界分析

  • ファイブフォース分析
  • 疫学分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 新型コロナウイルス感染症(COVID-19)の影響分析

  • 新型コロナウイルス感染症(COVID-19)の市場への影響
    • コロナ以前のシナリオ
    • 現在のシナリオ
    • コロナ以後のシナリオ
  • コロナ渦中の価格のダイナミクス
  • 需要と供給のスペクトル
  • コロナ渦中の市場に対する政府イニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 ペニシリン製剤市場:ソース別

  • イントロダクション
    • 市場規模・前年比成長率の分析:ソース別
    • 市場魅力指数:ソース別
  • 天然
  • 半合成

第8章 ペニシリン製剤市場:クラス別

  • イントロダクション
    • 市場規模・前年比成長率の分析:クラス別
    • 市場魅力指数:クラス別
  • アミノペニシリン
  • 緑膿菌ペニシリン
  • ベータラクタマーゼ阻害剤
  • ペニシリナーゼ耐性ペニシリン

第9章 ペニシリン製剤市場:投与経路別

  • イントロダクション
    • 市場規模・前年比成長率の分析:投与経路別
    • 市場魅力指数:投与経路別
  • 口腔
  • 非経口

第10章 ペニシリン製剤市場:地域別

  • イントロダクション
    • 市場規模・前年比成長率の分析:地域別
    • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 市場力学
    • 市場規模・前年比成長率の分析:ソース別
    • 市場規模・前年比成長率の分析:クラス別
    • 市場規模・前年比成長率の分析:投与経路別
    • 市場規模・前年比成長率の分析:国別
  • 欧州
  • 南米
  • アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク
  • 注目すべき主要企業のリスト
  • 破壊的技術を持つ企業のリスト
  • スタートアップ企業のリスト

第12章 企業プロファイル

  • Qpex Biopharma
    • 企業概要
    • 製品ポートフォリオと詳細
    • 主なハイライト
    • 財務情報
  • Pfizer, Inc.
  • Novartis AG
  • Sanofi S.A
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries
  • F. Hoffmann-La Roche AG
  • Shanghai Hegno Pharmaceutical Holding Co., Ltd.
  • Jiangxi Tianxin Pharmaceutical Co. Ltd.
  • Nanjing Pharmaceutical Factory Co. Ltd.

第13章 DataM Intelligenceについて

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH3989

Penicillin Drug Market Overview

The penicillin drug market size was valued at US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).

In the penicillin group of drugs Penicillin V is an antibiotic. It fights bacteria in the body. It is used to treat different infections caused by bacteria, such as ear infections.

Penicillin Drug Market Dynamics

The rising prevalence of bacterial infection and demand for effective and newer antibiotics will drive the penicillin drug market in the forecast period.

The rising prevalence of bacterial infection will drive the penicillin drug market

Bacterial infections show a large impact on public health. The disease can occur in any body and can be caused by the organism itself or by the response of the body to its presence. Bacteria are transmitted to humans through water, food, air, or living vectors. The modes of transmission of bacterial infection are contact, airborne, droplet, vectors, and vehicular. Respiratory infections were the most common (45.5%), followed by blood (23.3%) and urinary (16.1%). Gram-negative bacteria were common Acinetobacter baumannii (20.9%), Klebsiella pneumoniae (19.7%), Escherichia coli (18.3%), and Pseudomonas aeruginosa (14.0%). There is a resistance with high prevalence to common antibiotics. The global prevalence of multidrug-resistant (MDR) bacteria was 34% (95% confidence interval 31%-37%).

Penicillin is administered to patients with an infection caused by bacteria. According to the National Library of Medicine, few types of bacterial infections that can be treated with penicillin include gonorrhea, pneumonia,meningitis, syphilis and strep throat. It may be used to prevent dental infections. As an antibiotic, penicillin kills bacteria or prevents them from growing and multiplying. The drug works by attacking enzymes that build the cell walls of bacteria. Different kinds of penicillin are used for various infections. Some types of penicillin are amoxicillin, ampicillin, Augmentin, penicillin G and penicillin V.

The rising demand for effective and newer antibiotics will drive the penicillin drug market in the forecast period

Discovery and lauch of new antibiotics to market is a formidable challenge but it needs to be addressed if we want to be better protected against the growing threat of drug-resistant infections. The discovery of penicillin the first antibiotic has revolutionized modern medicine. Antibiotics have become common class of drugs used to treat and prevent infections and are used incomplex surgeries from caesarean sections to hip replacement surgeries and organ transplants. But they are not as effective as they used to be. Over time certain bacteria, so-called 'superbugs,' have learned and adapted to resist the effects of the drugs designed to kill them. The collective overuse of antibiotics in animals, humans and plants has accelerated this process. In recent times, infections due to drug-resistant have become serious threat to people's health. Every year many lives are lost because of infections that cannot be treated with existing drugs. To save modern medicine discovery of new antibiotics able to kill drug-resistant bacteria is essential.

Over the time, bacteria will learn to resist the new drugs. To stay ahead in this constant race against superbugs, we also need innovations in developing diagnostics, vaccines and better prevention control and surveillance. According to the WHO and the Pew Charitable Trust, there are currently between 40 and 50 antibiotics in clinical development.

The rising number of multi-drug resistant (MDR) pathogens will hamper the penicillin drug market

Representing a serious problem for public health antibiotic resistance is one of the greatest challenges in the health system. Initially, these strains were restricted to the hospital environment, but now they are found everywhere. Globalization, aquaculture, use of multiple broad-spectrum agents, excessive use of antibiotics in animal husbandry and lack of good antimicrobial stewardship are listed as the factors responsible for the spread of antibiotic resistance. The increase in the rate of antibiotic-resistant pathogens implies having fewer antimicrobial agents to treat infections.

Huge amounts of antibiotics used for human therapy, farm animals and even fish in aquaculture is used in the selection of pathogenic bacteria resistant to multiple drugs. In bacteria multidrug resistance is generated by one of two mechanisms. Initially, these bacteria accumulates multiple genes, each coding for resistance to a single drug within a single cell. This accumulation occurs typically on-resistance (R) plasmids. Second, multidrug resistance occurs by the increased expression of genes that code for multidrug efflux pumps, extruding a wide range of drugs. Multidrug resistance in bacteria occurs by the accumulation of genes on resistance (R) plasmids or transposons, with each code for resistance to a specific agent, and by the multidrug efflux pumps action,each of which pumps out more than one drug type.

COVID-19 Impact Analysis

The healthcare industry has been affected by COVID-19. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and negative health from the COVID-19 pandemic. This has seen to affect the penicillin drug market as many have stopped manufacturing units.

Penicillin Drug Market Segment Analysis

The natural penicillin segment will dominate the market

The two so-called natural penicillins are both produced biosynthetically from Penicillium chrysogenum by fermentation. Benzylpenicillin (penicillin G) is formed if phenylacetic acid is added to the culture medium, and Phenoxymethylpenicillin (penicillin V) is formed when phenoxyacetic acid is added. The first antibiotics natural Penicillins were used in clinical practice. They are based on the penicillin- G structure and inhibit bacterial cell wall synthesis and are generally bactericidal. Natural penicillins are effective against gram-positive bacteria such as staphylococci, streptococci and gram-negative bacteria such as meningococci, Treponema, Borrelia and Leptospira.

They include penicillin G for parenteral use and penicillin V for oral use only. These drugs primarily indicate infections caused by gram-positive organisms, including anaerobes (except Bacteroides fragilis). Spirochetes and some gram-negative organisms are susceptible. However, others require higher concentrations. The Pseudomonas aeruginosa and Enterobacteriaceae are resistant. Penicillin V should not be used for serious infections due its variable and incomplete absorption.

Aminopenicillin class will dominate the penicillin drug market

The aminopenicillin class of semisynthetic penicillins contains an amino substitution in the phenyl acetamido side chain of the penam nucleus, providing a polar charge on the molecule that allows activity against gram-negative pathogens, including Escherichia coli and Haemophilus influenzae. However, aminopenicillins are not stable to staphylococcal penicillinases or the hundreds of different B-lactamases elaborated by gram-negative pathogens. Their activity against other gram-positive organisms, such as group A and group B Streptococcus spp., is excellent, and activity against most enterococci is equivalent to or better than penicillin G.

Aminopenicillins are a group of antibiotics belonging to the penicillin family with an additional amino group that enhances its antibacterial activity. They are used for a range of wide infections such as urinary, respiratory, skin, and gastrointestinal infections. Aminopenicillins are indicated to treat upper respiratory tract infections, lower respiratory tract infections, bacterial gastroenteritis (ampicillin only), meningitis, bacterial endocarditis and urinary tract infections caused by susceptible (i.e., non-B-lactamase-producing) organisms.

The oral segment will dominate the penicillin drug market

Penicillins (except bacampicillin tablets, penicillin V, amoxicillin,pivmecillinam and pivampicillin) are best taken with a glass full (8 ounces) of water on an empty stomach (either 1 hour before or 2 hours after meals) unless directed by the doctor. Pivmecillinam, penicillin V, pivampicillin and amoxicillin may be taken on a full or empty stomach.

Amoxicillin in liquid form may be taken by itself or mixed with different formulas or other cold drinks. If mixed with other liquids,it is to be taken timmediately after mixing.One should be sure to drink all the liquid to get the full dose of medicine. The liquid form of this medicine is best to be taken with a full glass of water on an empty stomach unless otherwise directed by the doctor. The tablet form of the medicine can be taken on a empty or full stomach. Oral tablet of Penicillin V is used to treat certain infections caused by bacteria. It won't treat infections caused by viruses. This drug's bacterial infections include streptococcal upper respiratory tract infections, scarlet fever, and erysipelas infections.

Penicillin Drug Market Geographical Analysis

North America region will dominate the penicillin drug market

The increasing prevalence of bacterial infections and major key players will dominate the penicillin drug market. In the U.S., according to the report, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35,000 people die as a result. The U.S. FDA approved Recarbrio (a combination of relebactam and imipenem-cilastatin) to treat hospital acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older. Recarbrio was previously FDA-approved to treat patients with complicated urinary tract infections and intra-abdominal infections with limited or no alternative treatment options.

Penicillin is a prescription medication and should not be used casually. Due to this, penicillin OTC (over the counter) is not available, and one cannot just buy penicillin online in the United States.

Penicillin Drug Market Competitive Landscape

Major key players in the penicillin drug market are Pfizer, Inc., Novartis AG, Sanofi S.A., Astellas Pharma, Inc., GlaxoSmithKline plc, Merck Co. and Inc., Fujifilm Toyama Chemical Co. Ltd., Sun Pharmaceutical Industries, Lupin Limited, Cipla Limited, Bayer AG, F. Hoffmann-La Roche AG, Daiichi Sankyo Company Ltd., Qpex Biopharma, Shanghai Hegno Pharmaceutical Holding Co., Ltd., Jiangxi Tianxin Pharmaceutical Co. Ltd. and Nanjing Pharmaceutical Factory Co. Ltd.

Penicillin Drug Market Key Companies to Watch

Qpex Biopharma

Overview: A resistance-focused infectious disease company, Qpex Biopharma, Inc. is on a mission to make both a sustainable and dramatic improvement in patient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, they create novel products and development strategies that overcome multi-drug resistance. They are advancing a robust portfolio of treatments that will bring innovation to antibiotic development and deliver the right treatments to patients in the right settings.

Product Portfolio: The company comprises drug discovery, anti-infective therapies, antibiotics, drug development, drug resistance, microbiology, and boron chemistry.

Key Development: Qpex Biopharma, Inc., a resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, has announced the initiation of a Phase 1 study of QPX9003, a next-generation intravenous (IV)-administered synthetic polymyxin for infections caused by gram-negative drug-resistant pathogens.

Why Purchase the Report?

  • Visualize the composition of the penicillin drug market Segmentation By Source and By Class androute of administration , highlighting the key commercial assets and players.
  • Identify commercial opportunities in the penicillin drug market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of penicillin drug market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The penicillin drug market the report would provide an access to an approx. 60 market data table, 50 figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Penicillin Drug Market - By Source

  • Natural
  • Biosynthesis
  • Semi synthesis

Penicillin Drug Market - By Class

  • Aminopenicillin
  • Antipseudomonal Penicillin
  • Beta-lactamase Inhibitor
  • Penicillinase-resistant Penicillin

Penicillin Drug Market - By Route of Administration

  • Oral
  • Parenteral

Penicillin Drug Market - By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa

Table of Contents

1. Penicillin Drug Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Penicillin Drug Market - Market Definition and Overview

3. Penicillin Drug Market - Executive Summary

  • 3.1. Market Snippet By Source
  • 3.2. Market Snippet By Class
  • 3.3. Market Snippet By Route of Administration
  • 3.4. Market Snippet By Region

4. Penicillin Drug Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising prevalence of bacterial infection will drive the penicillin drug market
      • 4.1.1.2. The rising demand for effective and newer antibiotics will drive the penicillin drug market in the forecast period
    • 4.1.2. Restraints:
      • 4.1.2.1. The rising number of multi-drug resistant (MDR) pathogens will hamper the penicillin drug market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Penicillin Drug Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Penicillin Drug Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Penicillin Drug Market - By Source

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source Segment
    • 7.1.2. Market Attractiveness Index, By Source Segment
  • 7.2. Natural*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Air driven turbines
  • 7.4. Semi synthesis

8. Penicillin Drug Market - By Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class
    • 8.1.2. Market Attractiveness Index, By Class
  • 8.2. Aminopenicillin*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Antipseudomonal Penicillin
  • 8.4. Beta-lactamase Inhibitor
  • 8.5. Penicillinase-resistant Penicillin

9. Penicillin Drug Market - By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Parenteral

10. Penicillin Drug Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

11. Penicillin Drug Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch
  • 11.5. List of Company with disruptive technology
  • 11.6. List of Start Up Companies

12. Penicillin Drug Market - Company Profiles

  • 12.1. Qpex Biopharma*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Pfizer, Inc.
  • 12.3. Novartis AG
  • 12.4. Sanofi S.A
  • 12.5. GlaxoSmithKline plc
  • 12.6. Sun Pharmaceutical Industries
  • 12.7. F. Hoffmann-La Roche AG
  • 12.8. Shanghai Hegno Pharmaceutical Holding Co., Ltd.
  • 12.9. Jiangxi Tianxin Pharmaceutical Co. Ltd.
  • 12.10. Nanjing Pharmaceutical Factory Co. Ltd.

LIST NOT EXHAUSTIVE

13. Penicillin Drug Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us